PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2010-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00721422
- Locations
- 🇺🇸
Pfizer Investigational Site, Miami, Florida, United States
A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection
- First Posted Date
- 2008-07-22
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 35
- Registration Number
- NCT00720434
- Locations
- 🇵🇷
Pfizer Investigational Site, Santurce, Puerto Rico
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1674
- Registration Number
- NCT00716625
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 472
- Registration Number
- NCT00716820
Effect Of Treatment With Oral Zolpidem On Polysomnography And Actigraphy Measures In Healthy Volunteers
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2009-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT00716521
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study Evaluating The Efficacy Of Varenicline In Cessation Of Oral Smokeless Tobacco Use
- First Posted Date
- 2008-07-16
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 432
- Registration Number
- NCT00717093
- Locations
- 🇸🇪
Pfizer Investigational Site, Umea, Sweden
Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
- Conditions
- Anxiety Disorders
- Interventions
- First Posted Date
- 2008-07-15
- Last Posted Date
- 2008-10-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 169
- Registration Number
- NCT00715039
- Locations
- 🇺🇸
Pfizer Investigational Site, Cincinnati, Ohio, United States
Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT00714116
- Locations
- 🇺🇸
Arthritis & Rheumatology Care Center, South Miami, Florida, United States
🇺🇸MRA Clinical Research, South Miami, Florida, United States
🇺🇸Miami Research Associates, South Miami, Florida, United States
Registry For Patients Treated With BeneFix In Usual Care Setting In Germany
- First Posted Date
- 2008-07-14
- Last Posted Date
- 2018-10-25
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 80
- Registration Number
- NCT00714415
- Locations
- 🇦🇹
Allgemeines Krankenhaus Linz, Kinderklinik, Linz, Austria
🇩🇪Werlhof-Institut für Haemostaseologie GmbH, Hannover, Niedersachsen, Germany
🇩🇪Klinikum der Martin-Luther-Universitaet Halle-Wittenberg, Halle, Germany
Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2018-10-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT00712348
- Locations
- 🇮🇱
Shaare Zedek Medical Center, Jerusalem, Israel
🇬🇧Royal Free Hospital, London, United Kingdom
🇬🇧Lysosomal Disorders Service, Addenbrookes Hospital NHS Trust, Cambridge, United Kingdom